Continuous-Flow Supercritical CO2 Platform for In-Situ Synthesis and Purification of Small Molecules for Drug Discovery
Ver/ Abrir
Impacto
Scholar |
Otros documentos de la autoría: Alcalde, Sergio; Porcar Garcia, Raul; De la Puente, María Luz; Cumming, Graham; Mateos, Carlos; García-Losada, Pablo; Anta, Cristina; Rincón, Juan A.; Garcia-Verdugo, Eduardo
Metadatos
Mostrar el registro completo del ítemcomunitat-uji-handle:10234/9
comunitat-uji-handle2:10234/7053
comunitat-uji-handle3:10234/8639
comunitat-uji-handle4:
INVESTIGACIONMetadatos
Título
Continuous-Flow Supercritical CO2 Platform for In-Situ Synthesis and Purification of Small Molecules for Drug DiscoveryAutoría
Fecha de publicación
2023-02-03Editor
American Chemical SocietyCita bibliográfica
ALCALDE, Sergio, et al. Continuous-Flow Supercritical CO2 Platform for In-Situ Synthesis and Purification of Small Molecules for Drug Discovery. Organic Process Research & Development, 2023, vol. 27, no 2, p. 276-285.Tipo de documento
info:eu-repo/semantics/articleVersión de la editorial
https://pubs.acs.org/doi/full/10.1021/acs.oprd.2c00253Versión
info:eu-repo/semantics/acceptedVersionPalabras clave / Materias
Resumen
The use of supercritical CO2 (scCO2) as an enabling technology paves the way for an efficient in-line integration of
the synthesis and purification of organic molecules. The scCO2 platform presented here provides a ... [+]
The use of supercritical CO2 (scCO2) as an enabling technology paves the way for an efficient in-line integration of
the synthesis and purification of organic molecules. The scCO2 platform presented here provides a streamlined process to produce a
diverse family of triazoles, common drug precursors, by 1,3-dipolar copper-catalyzed azide-alkyne cycloaddition (CuAAC, Huisgen
reaction), also decreasing the environmental impact by significantly reducing the use of traditional solvents. To further exemplify the
potential of this scCO2 platform, the synthesis and purification of rufinamide, a drug used to treat seizures associated with Lennox−
Gastaut syndrome, is also reported. [-]
Publicado en
Organic Process Research & Development, 2023, vol. 27, no 2.Entidad financiadora
Ministerio de Ciencia e Innovación | Universitat Jaume I | Generalitat Valenciana | Centro de Investigación Lilly S.A.
Código del proyecto o subvención
PID2021- 124695OB-C22 | UJIB2019-40 | AICO/2021/139
Derechos de acceso
© 2023 American Chemical Society. "This document is the Accepted Manuscript version of a Published Work that appeared in final form in Organic Process Research and Development, copyright © 2023 American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see https://pubs.acs.org/doi/full/10.1021/acs.oprd.2c00253."
http://rightsstatements.org/vocab/InC/1.0/
info:eu-repo/semantics/openAccess
http://rightsstatements.org/vocab/InC/1.0/
info:eu-repo/semantics/openAccess
Aparece en las colecciones
- QUIO_Articles [694]